Development of an immunoassay for determination of NGAL-dimer levels in patients with cardiovascular diseases
The aim of this study is to develop a FRET-based immunoassay to measure the protein homodimer of Neutrophil Gelatinase-Associated Lipocalin (NGAL) concentrations in human blood samples and tissue homogenates.
NGAL is a small soluble glycoprotein and is present in blood as a monomer, homo- and heterodimer. NGAL is recognized as a marker of acute kidney injury. NGAL-dimer is stored and secreted by human neutrophils and comprise > 50% of NGAL in human carotid artery plaque. Recent data have established a strong link between NGAL and outcome of cardiovascular diseases. High plasma NGAL predicts all-cause mortality and major adverse cardiovascular events in ST-segment elevation myocardial infarction, as well as in the general population. In patients with coronary artery disease, levels of circulating NGAL reflect the degree of inflammatory process.
Existing data is mainly based on total-NGAL levels and does not differentiate between the different molecular forms. Assays directed towards the NGAL-dimer may provide more accurate estimates of biomarker characteristics and function of NGAL in cardiovascular diseases.
Alexander er medicinstuderende på 7. semester og har været forskningsaktiv på Hjerte-, Lunge-, Karkirurgisk afdeling, Aarhus Universitetshospital siden april 2016. Har desuden været gæsteforsker på Sahlgrenska Universitetshospital, Göteborg, Sverige og Landspitali, Reykjavik, Island.
Han har været medlem af SMS siden 2017.